Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
171.91B
Market cap171.91B
Price-Earnings ratio
9.47
Price-Earnings ratio9.47
Dividend yield
3.17%
Dividend yield3.17%
Average volume
17.76M
Average volume17.76M
High today
$38.90
High today$38.90
Low today
$38.23
Low today$38.23
Open price
$38.40
Open price$38.40
Volume
11.43M
Volume11.43M
52 Week high
$64.16
52 Week high$64.16
52 Week low
$35.12
52 Week low$35.12

NVO News

MarketWatch 25m
Novo Nordisk strikes second licensing deal since frosty capital-markets day

Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy. Novo Nordisk...

Novo Nordisk strikes second licensing deal since frosty capital-markets day
Financial Times 1h
Novo buys rights to Chinese weight-loss pill in $2.6bn deal - Financial Times

...

Novo buys rights to Chinese weight-loss pill in $2.6bn deal - Financial Times
Seeking Alpha 4h
Novo Nordisk strikes $2.6B obesity drug deal with China's Hengrui

Jiangsu Hengrui Pharmaceuticals has agreed to license global rights to its experimental obesity drug HRS-1596 to Novo Nordisk (NVO) in a deal worth up to $2.6B....

Novo Nordisk strikes $2.6B obesity drug deal with China's Hengrui

More NVO News

The Wall Street Journal 5h
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma

Novo Nordisk will pay Hengrui $300 million upfront, with the rest of the potential deal value tied to milestones. Andrew Silver / Reuters Novo Nordisk NOVO.B -...

Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
TipRanks 14h
Option traders moderately bearish in Novo Nordisk with shares down 0.22%

Option traders moderately bearish in Novo Nordisk (NVO), with shares down 8c near $38.72. Options volume roughly in line with average with 78k contracts traded...

TipRanks 18h
Novo Nordisk Details Progress of DKK 15 Billion Share Buyback Programme

Novo Nordisk ( (NVO) ) has shared an announcement. On 28 September 2026, Novo Nordisk reported progress on its ongoing share repurchase programme, part of a br...

MarketWatch 21h
Taking Ozempic? A routine eye exam could help you understand your risk for vision loss.

A routine eye exam could help the millions of Americans taking GLP-1s better understand if they are at risk for a rare form of vision loss. As part of a routin...

Taking Ozempic? A routine eye exam could help you understand your risk for vision loss.
TipRanks 23h
Beyond the Semiconductor Names: Four ADRhedged™ ETFs Covering Enterprise Software, Healthcare and Energy

Ringing the Bell for a Ten-Fund Lineup Precidian Investments, the sponsor behind the ADRhedged™ platform, rang the opening bell at the New York Stock Exchange o...

Simply Wall St 1d
NIKE Stock And 2 Other Great Dividend Stocks

The bond market has shifted into a world of 5% yields, and income investors suddenly have real competition for their cash. When government bonds pay more, weake...

NIKE Stock And 2 Other Great Dividend Stocks
Nasdaq 1d
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Key Points Bristol Myers Squibb's Growth Portfolio sales rose 15% in the second quarter, and management raised its 2026 revenue guidance to $49 billion to $50...

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.